NFKB1 and neoplasm: As a key factor contributing to tumor survival and progression during colorectal cancer therapy (5,6), NF-κB can be activated by CPT-11, it is already upregulated in most colorectal cancers during early treatment (7) and could be a potential chemo-resistance mechanism in malignant cells (8,9) that will reduced chemosensitivity.